Section 32

Section 32 is a prominent venture capital firm based in San Diego, California, founded in 2017 by Bill Maris, the former CEO and founder of Google Ventures (now GV). The firm distinguishes itself by investing at the convergence of technology, healthcare, and life sciences, leveraging Maris's deep expertise in both venture capital and the tech industry. Their investment thesis centers on supporting companies that are developing groundbreaking solutions to complex challenges, particularly those with the potential for significant societal impact and market disruption.

Section 32 employs a multi-stage investment strategy, engaging with companies from early seed rounds through growth equity stages, though they are particularly active in Series A and B investments. The firm is known for its hands-on approach, providing strategic guidance and leveraging its extensive network to support portfolio companies. Since its inception, Section 32 has demonstrated remarkable growth in its capital base. It successfully closed its first fund at $150 million in 2017, followed by a $300 million Fund II in 2019, a $525 million Fund III in 2021, and most recently, an impressive $800 million for Fund IV in 2023. This rapid increase in fund size underscores investor confidence and expands the firm's capacity for larger and more impactful investments.

While Section 32 invests globally, its primary focus remains within the United States, particularly in innovation hubs. The firm typically writes initial checks ranging from approximately $1 million for early-stage opportunities to upwards of $25 million for more mature Series A or B rounds where they take a lead position. Their investment philosophy emphasizes long-term partnerships with visionary founders, providing not just capital but also strategic insights and operational support. Section 32's portfolio reflects its diverse interests, including companies developing novel therapeutics, advanced diagnostics, AI-powered healthcare solutions, and disruptive biotechnologies, solidifying its position as a key player in the intersection of health and technology venture capital.